Lv6
1660 积分 2021-04-21 加入
Why, when, and how to treat migraine patients?
2天前
求助中
The Interictal State of Migraine: Understanding the Hidden Burden Between Attacks
2天前
已完结
Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort
7天前
已完结
Burden of Disease and Unmet Needs in Atopic Dermatitis: Results From a Patient Survey
7天前
已完结
Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendations
7天前
已完结
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
12天前
已完结
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
12天前
已完结
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
12天前
已完结
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
12天前
已完结
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
12天前
已完结
皖公网安备34019202002308
